To provide managed care pharmacists with up-to-date information and practical strategies for translating the latest medical and scientific developments and applications into the best possible patient outcomes for individuals with juvenile arthritis.
This activity is designed for managed care pharmacists. No prerequisites required.
The University of Tennessee College of Pharmacy takes responsibility for the content, quality, and scientific integrity of this CE activity. At the conclusion of this activity, the participant should be able to:
- Summarize the epidemiology, pathophysiology, and clinical presentation of juvenile arthritis (JA).
- Integrate knowledge of the efficacy and safety of current and emerging treatments into strategic therapy regimens for patients with JA.
- Compare and contrast the mechanisms of action, side effects, and limitations of traditional biologic treatment agents for JA to costimulator modulators.
- Describe the impact pharmacists can have on therapies for JA on the family and the payer, including clinical benefit and pharmacoeconomic considerations.
The University of Tennessee College of Pharmacy (UTCOP) is accredited by the Accreditation Council for Pharmacy Education (ACPE) to provide continuing education for pharmacists.
CREDIT DESIGNATION STATEMENT
This knowledge-based program is sponsored by The University of Tennessee College of Pharmacy who is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Successful completion of this program will provide 2 contact hours credit (0.2 CEUs). Successful completion includes reading the materials, completing the post-test with a score of at least 70%, and completing the program evaluation. If you score less than 70% on the post-test, you will be allowed to complete the post-test 1 more time. A statement of CE credit will be available online immediately following successful completion of the program. ACPE program #064-000-08-207-H01-P.
This continuing education activity was produced under the supervision of Glen E. Farr, PharmD, Associate Dean for Continuing Pharmacy Education, University of Tennessee College of Pharmacy.
The estimated time to complete this educational activity: 2 hours.
Release date: September 15, 2008. Expiration date: September 15, 2010.
The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. This enduring material is produced for educational purposes only. Use of University of Tennessee College of Pharmacy name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.
A participant, sponsor, faculty member, or other individual wanting to file a grievance with respect to any aspect of a program sponsored or co-sponsored by the UTCOP may contact the Associate Dean for Continuing Education in writing. The grievance will be reviewed and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level of review.
This program is supported by an educational grant from Bristol-Myers Squibb Company.